A comparison of current neuroblastoma chemotherapeutics

Bibliography

• BRODEUR GM, CASTLEBERRY RP Neuroblastoma. In: Principles and practice of pediatric oncology Pizzo PA, Poplack DG (Eds), JB Lippincott, Philadelphia, USA (1997)761–797.
   Google Scholar
• BERTHOLD F, HERO B, KREMENS B et al.: Neuroblastoma. Current drug therapy recommendation as part of the total treatment approach. Drugs (2000) 59:1261–1277.
   Google Scholar
• BRODEUR GM, AMBROS PF: Geneticand biological markers of prognosis in Neuroblastoma. In: Neuroblastoma. Brodeur, Sawada, Tsuchida, Votate (Eds). Elsevier (2000):355–369. .A good updated revision.
   Google Scholar
• CARON H, VAN SLUIS P, DE KRAKERJ et al.: Allelic loss of chromosome lp as a predictor of unfavourable outcome in patiens with neuroblastoma. N Engl. Med. (1996) 334:225-230. Importance of chromosome lp deletion.
   Google Scholar
• MARTS JM, MATTHAY KK: Molecular biology of neuroblastoma. Clin.Oncol. (1999) 17(7):2264–2279.
   Google Scholar
• BOWN N, COTTERILL S, LASTOWSKA m et al.: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl. Med. (1999) 340 :1954–1961.
   PubMed Web of Science ®Google Scholar
• ••The first series who describes theimportance of the gain of chromosome 17q.
   Google Scholar
• SHIMADA H, CHATTEN J, NEWTON WA et al: Histopathologic prognostic factors in neuroblastic tumours: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomata. I Natl. Cancer Inst. (1984) 73:405–416.
   PubMed Web of Science ®Google Scholar
• ••Description of the Shirnadahistopathological system.
   Google Scholar
• SHIMADA H, AMBROS I, DEHNER LP et al.: Terminology and morphologic criteria of neuroblastic tumours. Recommendations by the International Neuroblastoma Pathology Committee. Cancer (1999) 86:349–363.
   Google Scholar
• MOSSERI V, MICHON J, DE BERNARDI B et al.: Surgery as only treatment for INSS Stage 2 neuroblastoma without MYCN amplification: final report of an European Prospective trial. Advances in Neuroblastoma Research, Paris, France (2002)43.
   Google Scholar
• PEREZ CA, MATTHAY KK, ATKINSON JB et al.: Biologic variables in the outcome of stage I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group Study. j Clin. Oncol (2000) 18(1):18–26. Shows how biological factors marked an evolution in localised neuroblastoma.
   Google Scholar
• HAASE GM, ATKINSON JB, STRAM DO et al.:Surgical management and outcome of locoregional neuroblastoma. Comparison of the Children's Cancer Group and the International Staging System." Pediatr. Surg. (1995) 30:289–295.
   Google Scholar
• HAYES FA, GREEN AA, O'CONNOR DM.: Chemotherapeutic management of epidural neuroblastoma. Med. Ped. Onco/(1989) 17:6–8.
   Google Scholar
• PLANTAZ D, RUBIE H, MICHON J et al.: The treatment of neuroblastoma with intra-spinal extension with chemotherapy followed by the surgical removal of residual disease: a prospective study of 42 cases. Cancer (1996) 78:311–319.
   PubMedGoogle Scholar
• ••The largest series of intraspinal extensiontreated with chemotherapy.
   Google Scholar
• NICKERSON HJ, MATTHAY KK, SEEGER RC: Favourable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group Study. .1. Clin.Oncol (2000) 18(3):477–486.
   Google Scholar
• ••Most children with neuroblastoma Stage IVneed only supportive care.
   Google Scholar
• HSU LL, EVANS AE, D'ANGIO GJ: Hepatomegaly in neuroblastoma stage 4S: criteria for treatment of the vulnerable neonate. Med. Ped. Oncol (1996) 27:521–528.
   PubMedGoogle Scholar
• ••Grading system to predict outcome inStage 4S neuroblastoma.
   Google Scholar
• KATZENSTEIN HM, BOWMAN L, BRODEUR GM et al.: Prognostic significance of age, MYCN oncogene amplification, tumour cell ploidy and histology in 110 infants with stage D (5) neuroblastoma: the Pediatric Oncology Group Experience - A Pediatric Oncology Group Study.' Clin. Omni (1998) 16(02007–2017.
   Google Scholar
• ••A study of the prognostic factors inStage 4S neuroblastoma.
   Google Scholar
• RUBIE H, HARTMANN 0, MICHON J et al.: N-myc gene amplification is a major prognostic factor in localised neuroblastoma: results of the French NBL 90 Study." Clin. Omni (1997) 15(3):1171–1182.
   Google Scholar
• ••The importance of myc-Nin localised neuroblastoma.
   Google Scholar
• POWIS MR, IMESON JD, HOMES SJK: The effect of complete excision on stage III neuroblastoma: a report of the European Neuroblastoma Study Group. I Pediatr. Surg. (1996) 26:1119–1124.
   Google Scholar
• WEST D, SHAMBERGER RC, MACKLIS RIVI et al: Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. Clin. Oncol (1993) 11(1):84–90.
   Google Scholar
• RUBIE H, MICHON J, PLANTAZ D et al.: Unresectable localised neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Br.j Cancer (1998) 77(12):2310–2317.
   PubMedGoogle Scholar
• CASTEL V, BADAL MD, BEZANILLA JL et al.: Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Med. Pediatr. Omni (1995) 24:29–35.
   PubMedGoogle Scholar
• •A series of Stage 3 neuroblastoma homogeneously treated.
   Google Scholar
• GARAVENTA A, BERNARDI BD, PIANCA C et al.: Localised but unresectable neuroblatoma: treatment and outcome of 145 cases. " Clin. Oncol (1993) 11:1770–1779.
   Google Scholar
• MATTHAY KK, PEREZ C, SEEGER RC et al.: Successful treatment for stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group Study. Clin. Oncol (1998) 16(4):1256–1264.
   Google Scholar
• ••Treatment adapted to prospective biologyrisk in Stage 3 neuroblastoma.
   Google Scholar
• CHEUNG NK, KUSHNER BH, LA QUAGLIA MP et al: Survival form non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers. Ear: .1. Cancer (1997) 33(12):2117–2120.
   Google Scholar
• •Shows some neuroblastoma patients can be treated without chemotherapy.
   Google Scholar
• HERO B, SIMON T, BENZ-BOHN G et al.: Incidence and time frame of regression in stage 2 and 3 neuroblastoma. Advances in Neuroblastoma Research, Paris, France (2002):37.
   Google Scholar
• STROTHER D, SHUSTER JJ, MCWILLIAMS N et al: Results of the Pediatric Oncology Group Protocol 8104 for infants with stages D and DS neuroblastoma. Pediatr. Hematol Oncol (1995) 17(3):254–259.
   Google Scholar
• PAUL SR, TARBELL JN, KORF B et al.: Stage IV neuroblastoma in infants. Cancer (1991) 67:1493–1497.
   PubMedGoogle Scholar
• BERNARDI BD, PIANCA C, BONI L et al.: Disseminated neuroblastoma (stage IV and IVS) in the first year of life. Cancer (1992) 70:1625–1633.
   PubMedGoogle Scholar
• DUBOIS SG, KALIKA Y, LUKENS JN et al.: Metastatic sites in stage IV and IVS correlate with age, tumour biology and survival. Pediatr. Hematol Oncol (1999) 21(3):178–180.
   Google Scholar
• MINARD V, HARTMANN 0, PEYROULET MC et al.: Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology. Br. Cancer (2000) 83(8):973–979.
   Google Scholar
• •A SFOP Study on the prognostic factors of neuroblastoma in infants.
   Google Scholar
• SCHMIDT MI, LUKENS JM, SEEGER RC et al.: Biological factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group Study. I Clin. Omni (2000) 18(6):1260–1268.
   Google Scholar
• HAYES F.A, SMITH E.I. Neuroblastoma. In: Principles and practice of pediatric oncology Pizzo PA, Poplack DG (Eds), JB Lippincott, Philadelphia, USA (1989):607–622.
   Google Scholar
• MATTHAY KK, VILLABLANCA JD, SEEGER RC et al.: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N Engl I Med. (1999) 341:1165–1173.
   PubMed Web of Science ®Google Scholar
• ••A randomised study that demonstrates thesuperity of ABMT and 13-cis-RA.
   Google Scholar
• CASTEL V, CAICIETE A, NAVARRO S et al.: Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med. Pediatr. Oncol (2001) 37:537–542.
   PubMedGoogle Scholar
• •Shows that intensive therapies improve the initial results in high-risk neuroblastoma patients, but not so much long-term results.
   Google Scholar
• KANEKO M, TSUCHIDA Y, MUGISHIMA H et al: Intensified chemothearpy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. I Pediatr. Hematol Oncol (2002) 24(8):613–621.
   PubMedGoogle Scholar
• KANEKO M, NISHIRA H, MUGISHIMA H et al: Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Med. Pediatr. Oncol (1998) 31:1–7.
   PubMedGoogle Scholar
• BRODEUR GM, PRITCHARD J, BERTHOLD F et al.: Revisions of the International Criteria for neuroblastoma diagnosis, staging and response to treatment. Clin. Oncol (1993) 11(8):1466–1477.
   Google Scholar
• ••The current international classification ofextension disease and response followed by all groups.
   Google Scholar
• CHEUNG NK, HELLER G.: Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. Clin. Oncol (1991) 9:1050–1058.
   Google Scholar
• ••Shows there exists a relationship between dose, timing and outcome in high-risk neuroblastoma patients.
   Google Scholar
• PINKERTON RC, BLANC VICENT MMP, BERGERON C et al.: Induction chemotherapy in metastatic neuroblastoma- does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur: J. Cancer (2000) 36:1808–1815.
   Google Scholar
• ••Shows criticism of the previous work, anddoes not show a relation between the dose and the response rate.
   Google Scholar
• COZE C, HARTMANN 0, MICHON J et al.: NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J. Clin. Oncol (1997) 15(2):3433–3440.
   Google Scholar
• VALTEAU-COUANET D, MICHON J, PEREL Y et al: Results of NB97 SFOP protocol in children 1 year with stage 4 neuroblastoma. Advances in Neuroblastoma Research, Paris, France (2002) 44.
   Google Scholar
• BERTHOLD F, BURDACH S, KREMENS B et al: The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin. Padiatr. (1990) 202(4):262–269.
   PubMedGoogle Scholar
• BERNARDI BD, NICOLAS B, BONI L et al.: Disseminated neuroblastoma in children older than one year of age at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian cooperative Group forNeuroblastoma. Clin. Oncol (2003) 21(8):1592–1601.
   Google Scholar
• CASTEL V, NAVAJAS A, GARCIA-MIGUEL P et al.: Stage IV neuroblastoma in children over 1 year of age: results of a cooperative study using high-dose cisplatin-VM26 and cyclophosphamide-doxorrubicin as initial therapy. Int. J. Pediatr. Hematol Oncol (1995) 2:255–262.
   Google Scholar
• TWEEDLE DA, PINKERTON R, LEWIS IA et al.: OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Med. Pediatr. Oncol (2001) 36:239–242.
   PubMedGoogle Scholar
• KUSHNER B, LaQUAGLIA M, BONILLA MA et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.' Clin. Oncol (1994) 12(12):2607–2613.
   Google Scholar
• ••Shows better results than other publishedseries.
   Google Scholar
• CHEUNG NK, KUSHNER BH, LA QUAGLIA M et al: N7: a novel multi-modality therapy for high-risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med. Pediatr. Oncol (2001) 36(1):227–230.
   PubMedGoogle Scholar
• ••Shows better results than other publishedseries.
   Google Scholar
• PINKERTON CR: ENSG1 randomised study of high-dose melphalan in neuroblastoma. Bone Marrow Transplant. (1991) 7:112–113.
   PubMedGoogle Scholar
• •The first study that used high-dose melphalan and ABMT in the treatment of neuroblastoma.
   Google Scholar
• STRAM DO, MATTHAY KK, O'LEARY M et al.: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group Studies. j Clin. Oncol (1996) 14(9):2417–2426.
   Google Scholar
• ••This study demonstrated better results withABMT in a large, randomised series.
   Google Scholar
• LADENSTEIN R, PHILLIP T, LASSET C et al.: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplant. Solid Tumour Registry. I Clin. Oncol (1998) 16(3):953–965.
   PubMedGoogle Scholar
• MATTHAY KK, SEEGER RC, REYNOLDS P et al: Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J. Clin. Oncol (1994) 12(11):2382–2389. Shows ABMT is superior to allogenic BMT
   Google Scholar
• HARTMANN O, VALTEAU-COUANET D, VASSAL G et al.: Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem-cell transplantation. Bone Marrow Transplant. (1999), 23:789–795.
   PubMed Web of Science ®Google Scholar
• ••A multivariate study on prognostic factors in the setting of ABMT for high-risk neuroblastoma.
   Google Scholar
• LADENSTEIN R, POETS CHGER U, HARTMANN 0 et al: Megatherapy/SCT activity in pediatric solid tumours in Europe. Bone Marrow Transplant. (2000) 25\(Suppl. 1):71.
   Google Scholar
• VILLABLANCA JG, MATTHAY KK, SWIFT PS et al.: Phase I trial of etoposide, melphalan and local irradiation (CEM-LI) with purged autologous bone marrow transplantation (ABMT) for children with high risk neuroblastoma. Med. Pediatr. Oncol (1999) 33:170.
   Google Scholar
• FRAPPAZ D, MICHON J, COZE C et al: LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomata in children older than 1 year at diagnosis. J. Clin. Oncol (2000) 18(3):468–476.
   PubMedGoogle Scholar
• GARAVENTA A, RONDELLI R, LANINO E et al.: Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Bone Marrow Transplant. (1996) 18:125–130.
   PubMedGoogle Scholar
• SEEGER RC, REYNOLDS CP, GALLEGO R et al.: Quantitative tumour cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. I Clin. Oncol (2000) 18(24)4067–4076.
   Google Scholar
• ••Shows a relationship between residualbone marrow disease and outcome (inmunocitology).
   Google Scholar
• BURCHILL SA, KINSEY SE, PICTON S et al: Residual disease at the time of peripheral stem cell harvest in patients with advanced neuroblastoma. Med. Pediatr. Oncol (2001) 36:231–219.
   PubMedGoogle Scholar
• ••The same studied with PCR.
   Google Scholar
• SAARINEN UM, WIKSTROM S, MAKIPERNAA A: In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation. Clin. Oncul (1996) 14(10):2791–2802.
   PubMedGoogle Scholar
• REYNOLDS CP, KANE DI, EIHOM PA et al.: Response of neuroblastoma to retinoic acid in vitro and in vivo. Ping. Clin. Biol. Res. (1991) 366:203–211.
   PubMedGoogle Scholar
• MATTHAY KK, REYNOLDS CP.: Is there a role for retinoids to treat minimal residual disease in neuroblastoma?. Br. Cancer (2000) 83(9):1121–1123.
   Google Scholar
• KOHLER JA, IMESONJ, ELLERSHAW C et at A randomised trial of 13-cis-retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br.Cancer (2000) 83(9):1124–1127.
   Google Scholar
• CHEUNG NK, LAZARUS H, MIRALDI F et at Ganglioside GD2 specific monoclonal antibody 3F8:a Phase I study in patients with neuroblastoma and malignant melanoma. Clin. Once]. (1987) 5(9):1430–1440.
   PubMed Web of Science ®Google Scholar
• CHEUNG NK, KUSHNER B, CHEUNG IY et al.: AntiGD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Once]. (1998) 16(9):3053–3060.
   PubMed Web of Science ®Google Scholar
• ••The role of anti-GD2 antibodies in the treatment of high-risk neuroblastoma.
   Google Scholar
• CHEUNG NK, CHEUNG IY, CA&ETE A et al.: Antibody response to murine AntiGD2 monoclonal antibodies: correlation with patient survival. Cancer Res. (1994) 54:2228–2233.
   Google Scholar
• CHEUNG NK, GUO HF, CHEUNG IY: Correlation of anti-idiotype network with survival following antiGD2 monoclonal antibody 3F8 therapy of stage 4 neuroblastoma. Med. Pediatr. Once]. (2000) 35:635–637.
   PubMedGoogle Scholar
• MURRAY JK, CUNNINGHAM JE, BREWER H et al. : Phase I trial of murine monoclonal antibody 14G2a administered by prolong intravenoues infusion in patients with neuroectodermal tumours. Clin. Once]. (1994) 12(1):184–193.
   PubMed Web of Science ®Google Scholar
• OZKAYNAK FM, SONDEL PM, KRAILO MD et al.: Phase I study of chimeric human-murine antiganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopietic stem-cell transplantation: a Children's Cancer Group Study. Clin. Once]. (2000) 18(24):4077–4085.
   Google Scholar
• •The combined irnmunotherapy for treatment of minimal residual disease in high-risk neuroblastoma.
   Google Scholar
• HAND GRETINGER R, BAADER P, DOPFER R et al.: A Phase I study of neuroblastoma with the antiganglioside GD2 antibody 14 G2a. Cancer Immune]. Immunother. (1992) 35(3):199–204.
   PubMedGoogle Scholar
• UTTENREUTHER-FISCHER MM, HUANG CS, YU AL: Pharmacokinetics of human-mouse chimeric antiGD2 mAb ch 14.18 in a Phase I trial in neuroblastoma patients. Cancer Immune]. Immunother. (1995) 41(6):331–338.
   Google Scholar
• HOEFNAGEL CA: Nuclear medicine therapy of neuroblastoma. Ql. Nucl. Med. (1999) 4384:336–343.
   Google Scholar
• •The role of MIBG in diagnosis and treatment of neuroblastoma.
   Google Scholar
• XIAO WH, YU AL, SORKIN LA: Electrophysiological characteristics of primary afferent fibres after systemic administration of antiGD2 ganglioside antibody. Pant (1997) 69(1-2):145–151.
   Google Scholar
• VOUTE PA: Radionuclide therapy of neuroblastoma. 131I-Metaiodobenzylguanidine (MIBG) In: Neuroblastoma. Brodeur, Sawada, Tsuchida and Votate (Eds), Elsevier (2000):471.
   Google Scholar
• GARAVENTA A, BELLAGAMBA 0, LO PICCOLO MS et al: 131I-Metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br.Cancer (1999) 81(8):1378–1384.
   Google Scholar
• KLINGEBIEL T, BADER P, BARES R et al.: Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylduanidine, high dose chemotherapy and immunotherapy pilot study. Eur. Cancer (1998) 34(9):1398–1402.
   PubMed Web of Science ®Google Scholar
• YANIK GA, LEVINE JE, MATTHAY KK et al.: Pilot study of iodine-131-metaiodobnezylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. Clin. Once]. (2002) 20(8):2142–2149.
   PubMedGoogle Scholar